Drilldown: Medicines - Pharmacopedia

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Analgesic

or NDRI

or Research material

Use the filters below to narrow your results.

Other values:

None (135) · (multiple, generic dominant) (1) · (none, never marketed) (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Dolophine (1) · Duragesic (1) · Focalin, Focalin XR (1) · Nubain (1) · Nucynta (1) · O-DSMT (1) · Opana (1) · Ritalin, Ritalin LA, Concerta, Metadate CD, Daytrana, Quillivant XR (1) · Stadol (1) · Suboxone (1) · Talwin (1) · Vicodin (1)

5-HT2A agonist (26) · Monoamine releasing agent (9) · GABAA positive allosteric modulator (8) · CB1/CB2 agonist (7) · Dopamine/norepinephrine reuptake inhibitor (5) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Mu-opioid receptor agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · Potent mu-opioid receptor agonist (3) · Serotonin/norepinephrine/dopamine releasing agent (3) · Cathinone analogue; monoamine reuptake inhibitor (2) · Dopamine and norepinephrine reuptake inhibitor (2) · NMDA antagonist (2) · Prodrug of GHB (2)

Other values:

None (148) · ADHD, narcolepsy (1) · Mild to moderate pain; cough suppression (low-dose). (1) · No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) · '"`UNIQ--vote-00000150-QINU`"', '"`UNIQ--vote-00000151-QINU`"' (1)

None (150) · Adult: 15–60 mg every 4 hours as needed. (1) · No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1)

None (150) · Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (150) · 360 mg/day (1) · N/A (never approved) (1)

None (148) · intranasal; rectal and IV reported. (1) · Oral (3) · PO (only formulation marketed in the US). (1) · sublingual (1) · transdermal (1)

None (148) · 20–60 min (oral) (1) · 30–60 min (1) · 30–60 min (PO) (1) · ~20–40 min PO; faster sublingual/intranasal. (1)

None (148) · 4–6 hours (1) · 6–10 h subjective; full pharmacologic effect considerably longer. (1) · IR 3–5 h; LA/SR 6–8 h; Concerta 10–12 h; Daytrana ~9 h wear time (1) · IR 4–6 h; XR 8–12 h (1)

None (148) · 2.2 h (IR parent); ~3 h (XR parent) (1) · 2.5–3 hours (1) · 2–3 h (parent compound) (1) · Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1)

None (148) · Not formally characterized in humans. (1) · ~22–25% (1) · ~30% (high first-pass) (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (148) · Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Category C (1) · Pregnancy categories were retired by FDA in 2015. Limited reproductive data with small observational signal for cardiac malformations; risk-benefit decision, with many patients deferring ADHD treatment during pregnancy. See pregnancy_details for the full discussion. (1)

None (149) · Schedule II (2) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)

Showing below up to 152 results in range #1 to #152.

1

2

3

4

5

A

B

C

D

E

F

G

GBL

H

I

Isopropylphenidate

J

L

M

N

O

P

R

RTI-111

S

STS-135

T

U

U-47700

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"